AbbVie Forges $105 Million+ CD39 Inhibitor Alliance With Tizona

Privately-held Tizona Therapeutics snagged $105 million in upfront cash as its cancer antibody TTX-030 is the centerpiece of a collaborative effort with Illinois-based AbbVie. The two companies intend to combine their R&D capabilities with a focus on CD39-targeted therapeutics. CD39 is the enzyme that is responsible for a key immune regulatory action.
Read more...

;